// App-Quantinova.ai

4912 : Cytotoxic Effect of Bendamustine Combined with Kinase Inhibitors in Hematologic Cell Lines

Researchers

Presenter

  • Yuki Kojima

Principal Investigators

  • Yasuhiko Miyata

  • Hirokazu Nagai

Medical Centers

  • Clinical Rsch Cntr, National Hosp Organization, Nagoya Med Cntr, Nagoya, Japan

  • Department of Hematology, National Hospital Organization Nagoya Medical Center, Aichi, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Acute lymphoblastic leukemia

  • B cell lymphomas

  • Lymphomas

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Spleen tyrosine kinase

Drug/Treatment

  • Bendamustine

  • Enzastaurin

  • Ibrutinib

  • Rituximab

  • Idelalisib

  • Fostamatinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved